Glen Eagle Advisors, LLC Alkermes Plc. Transaction History
Glen Eagle Advisors, LLC
- $546 Billion
- Q2 2024
A detailed history of Glen Eagle Advisors, LLC transactions in Alkermes Plc. stock. As of the latest transaction made, Glen Eagle Advisors, LLC holds 20 shares of ALKS stock, worth $579. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20Holding current value
$579% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ALKS
# of Institutions
350Shares Held
183MCall Options Held
209KPut Options Held
89.4K-
Black Rock Inc. New York, NY29.1MShares$843 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA20MShares$579 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA14.4MShares$416 Million0.06% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD11MShares$319 Million0.03% of portfolio
-
State Street Corp Boston, MA9.22MShares$267 Million0.01% of portfolio
About Alkermes plc.
- Ticker ALKS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 164,254,000
- Market Cap $4.76B
- Description
- Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...